Novo Nordisk A/S
Senate launches investigation into high prices of Ozempic and Wegovy in the U.S.
The anti-diabetic medicine “Ozempic” (semaglutide) built by Danish pharmaceutical corporation Novo Nordisk. Joel Saget | AFP | Getty Illustrations or photos The U.S. Senate has launched an investigation into the high rate of Novo Nordisk‘s preferred fat decline and diabetes drugs Ozempic and Wegovy in the United States. The investigation into the Danish drugmaker was […]
Read More
More than 3 million Medicare patients could be eligible for coverage of Wegovy to reduce heart disease risks, study says
More than 3 million people with Medicare could be eligible for coverage of Wegovy now that the blockbuster weight loss drug is also approved in the U.S. for heart health, according to an analysis released Wednesday by health policy research organization KFF. But some eligible beneficiaries could still face out-of-pocket costs for the highly popular […]
Read More
Most people on weight loss drugs are spending less on restaurants and takeout, survey says
A food delivery messenger carries a take out bag outside aSweetgreen in Manhattan on September 14, 2023. Jeenah Moon | The Washington Post | Getty Images A highly popular group of weight loss and diabetes drugs is decreasing some consumers’ appetites — and also how much they spend on food. Most people taking those medications, […]
Read More
Promise of Eli Lilly’s weight-loss drug for sleep apnea adds another reason to own the stock
Eli Lilly ‘s weight-loss drug Zepbound showed promise as a treatment for sleep apnea — giving investors more confidence to keep owning the world’s most valuable health-care company even after it’s been crushing the S & P 500’s performance over the past three years. The study results released by Eli Lilly on Wednesday highlight the […]
Read More
Most doses of Eli Lilly’s Zepbound, Mounjaro in short supply through June, FDA says
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023. Brendan McDermid | Reuters Most doses of Eli Lilly‘s highly popular weight loss drug Zepbound and diabetes counterpart Mounjaro will be in short supply through the second quarter of this year as demand jumps, according […]
Read More
Eli Lilly’s weight loss drug Zepbound shows promise as a sleep apnea treatment in late-stage trials
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023. Brendan McDermid | Reuters Eli Lilly on Wednesday said its highly popular weight loss drug Zepbound showed the potential to treat patients with the most common sleep-related breathing disorder in two late-stage clinical trials. The […]
Read More
These are the top rated 5 companies to get the job done for in India, in accordance to LinkedIn
These are the 2024 best businesses in India, according to LinkedIn. Deepak Sethi | E+ | Getty Photos LinkedIn has unveiled its eighth yearly list of best corporations to work for in India, and corporations that prioritized its employees’ working experience and expansion dominated this year’s ranking. From mass layoffs to the adoption of generative […]
Read More
A prime Nvidia shareholder reveals his set off for marketing advancement shares
Nvidia shares have continued to soar this calendar year, up far more than 80%. But one of its best shareholders has unveiled why they’ve been selling the stock. Jennison Associates, the 15th largest shareholder of Nvidia, was an early investor in the chipmaker and now retains $7 billion worth of shares, or .57% of the […]
Read More
EU probe of weight loss and diabetes drugs like Wegovy, Ozempic finds no link to suicidal thoughts
Boxes of Wegovy made by Novo Nordisk are seen at a pharmacy in London, Britain March 8, 2024. Hollie Adams | Reuters European Union drug regulators found no evidence that highly popular weight loss and diabetes drugs such as Wegovy and Ozempic are linked to an increased risk of suicidal thoughts and self-injury, the regulator […]
Read More
Diabetes drug similar to Ozempic helped slow progression of Parkinson's disease in small trial
The coronal view of a human brain of a patient suffering from Parkinson’s disease Sherbrooke Connectivity Imaging Lab | Getty Images A highly popular class of drugs for diabetes and obesity is showing early potential to help patients with Parkinson’s disease, too. An older diabetes treatment called lixisenatide helped slow the progression of motor disability […]
Read More